Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Pr...

Date : 02/12/2020 @ 9:01PM
Source : GlobeNewswire Inc.
Stock : Reata Pharmaceuticals Inc (RETA)
Quote : 128.86  -6.51 (-4.81%) @ 5:00AM
Reata Pharmaceuticals share price Chart
After Hours
Last Trade
Last $ 128.86 ◊ 0.00 (0.00%)

Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Pr...

Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart

2 Months : From Feb 2020 to Apr 2020

Click Here for more Reata Pharmaceuticals Charts.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs post-market on February 19, 2020.

Reata’s management will host a conference call on February 19, 2020, at 4:30 p.m. ET.  The conference call will be accessible by dialing (844) 348-3946 (toll-free domestic) or (213) 358-0892 (international) using the access code: 1434037.  The webcast link is https://edge.media-server.com/mmc/p/jop4mn3n.  

Fourth-quarter and full-year 2019 financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at http://reatapharma.com/investors/ and will be available for 12 months after the call.  The audio recording and webcast will be accessible for at least 90 days after the event at http://reatapharma.com/investors/.

About Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (bardoxolone) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Contact:Reata Pharmaceuticals, Inc.(972) 865-2219http://reatapharma.com

Investors:Vinny JindalVice President, Strategy(469) 374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/

Media:Matt Middleman, M.D.LifeSci Public Relations(646) 627-8384matt.middleman@lifescipublicrelations.com

 

Latest RETA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200404 08:51:35